Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CET

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum(TM) (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum(TM) MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum(TM) MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt(®)

For full U.S. Prescribing Information for Fanapt(®), including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
01/19 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2017 Re..
01/11 VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
01/08 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Regu..
01/07 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2017 Re..
2017 VANDA PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Kansas (Dec. 28)
2017 VANDA PHARMACEUTICALS : New Vanda Pharmaceuticals’ Abstracts Suggest Circa..
2017 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
2017 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
2017 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
2017 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
More news
News from SeekingAlpha
01/19 Premarket analyst action - healthcare
01/10 YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/06 YOUR DAILY PHARMA SCOOP : Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafg..
2017 Vanda strikes out in appeal of thumbs down from European advisory group on Fa..
2017 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - ..